Follow up Protocol to the Open Label Phase I/II Study OPN-305-106: A Prospective, Open Label Phase I/II Study to Assess the Safety and Efficacy of Cycles of Intravenously Infused Doses of OPN-305 in Second-line and First-line Lower (Low and Intermediate-1) Risk Myelodysplastic Syndrome (MDS)
Phase of Trial: Phase I/II
Latest Information Update: 12 Apr 2018
At a glance
- Drugs OPN 305 (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Opsona Therapeutics
- 05 Apr 2018 Status changed from not yet recruiting to recruiting.
- 05 Apr 2018 Planned End Date changed from 1 Apr 2019 to 1 Jul 2019.
- 05 Apr 2018 Planned primary completion date changed from 1 Apr 2019 to 1 Jul 2019.